ORCHID PHARMA Financial Statement Analysis
|
||
|
The Revenues of ORCHID PHARMA have increased by 12.52% YoY .
The Earnings Per Share (EPS) of ORCHID PHARMA has increased by 8.15 % YoY. |
||
ORCHID PHARMA Last 5 Annual Financial Results
[BOM: 524372|NSE : ORCHPHARMA]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹922 Cr | ₹819 Cr | ₹666 Cr | ₹560 Cr | ₹450 Cr |
| Expenses | ₹811 Cr | ₹709 Cr | ₹582 Cr | ₹505 Cr | ₹399 Cr |
| Operating Profit (Excl OI) | ₹111 Cr | ₹111 Cr | ₹84 Cr | ₹55 Cr | ₹51 Cr |
| Other Income | ₹34 Cr | ₹31 Cr | ₹19 Cr | ₹9.00 Cr | ₹15 Cr |
| Interest | ₹15 Cr | ₹17 Cr | ₹33 Cr | ₹33 Cr | ₹52 Cr |
| Depreciation | ₹35 Cr | ₹33 Cr | ₹55 Cr | ₹87 Cr | ₹109 Cr |
| Profit Before Tax | ₹96 Cr | ₹92 Cr | ₹55 Cr | ₹-57 Cr | ₹-95 Cr |
| Profit After Tax | ₹96 Cr | ₹95 Cr | ₹55 Cr | ₹-57 Cr | ₹-95 Cr |
| Consolidated Net Profit | ₹100 Cr | ₹92 Cr | ₹46 Cr | ₹-1.95 Cr | ₹-117 Cr |
| Earnings Per Share (Rs) | ₹19.65 | ₹18.17 | ₹11.35 | ₹-0.48 | ₹-28.55 |
| PAT Margin (%) | 10.39 | 11.60 | 8.30 | -10.17 | -21.16 |
| ROE(%) | 7.86 | 10.23 | 8.27 | -8.75 | -13.43 |
| ROCE(%) | 8.05 | 9.35 | 9.11 | -2.32 | -3.53 |
| Total Debt/Equity(x) | 0.14 | 0.12 | 0.48 | 0.41 | 0.69 |
Key Financials |
||
| Market Cap | : | ₹ 2,602.4 Cr |
| Revenue (TTM) | : | ₹ 811.2 Cr |
| Net Profit(TTM) | : | ₹ 17.4 Cr |
| EPS (TTM) | : | ₹ 3.4 |
| P/E (TTM) | : | 149.9 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ORCHID PHARMA | -4.7% | -23.2% | -39% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.5% | 1.6% | 1.3% |
| DIVIS LABORATORIES | -2% | -4.3% | 3.3% |
| CIPLA | -3.9% | -9.1% | -18.4% |
| TORRENT PHARMACEUTICALS | -0.8% | 0.5% | 32% |
| DR REDDYS LABORATORIES | -2.7% | -1.6% | 6.9% |
| MANKIND PHARMA | -5.5% | -2% | -11.1% |
| ZYDUS LIFESCIENCES | -1.4% | -1.6% | -5.4% |
| LUPIN | 1.3% | 5.1% | 11.5% |
ORCHID PHARMA Revenues
[BOM: 524372|NSE : ORCHPHARMA]
| Y-o-Y | 12.52 % |
| 5 Yr CAGR | 19.63 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹922 Cr | 12.52 | |
| Mar2024 | ₹819 Cr | 23.05 | |
| Mar2023 | ₹666 Cr | 19.00 | |
| Mar2022 | ₹560 Cr | 24.33 | |
| Mar2021 | ₹450 Cr | - | |
ORCHID PHARMA Operating Profit
[BOM: 524372|NSE : ORCHPHARMA]
| Y-o-Y | -0.17 % |
| 5 Yr CAGR | 21.55 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹111 Cr | -0.17 | |
| Mar2024 | ₹111 Cr | 31.43 | |
| Mar2023 | ₹84 Cr | 54.45 | |
| Mar2022 | ₹55 Cr | 7.73 | |
| Mar2021 | ₹51 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -11.24 % |
| 5 Yr CAGR | 1.60 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 12% | -11.24 | |
| Mar2024 | 13.52% | 6.79 | |
| Mar2023 | 12.66% | 29.85 | |
| Mar2022 | 9.75% | -13.41 | |
| Mar2021 | 11.26% | - | |
ORCHID PHARMA Profit After Tax
[BOM: 524372|NSE : ORCHPHARMA]
| Y-o-Y | 8.13 % |
| 5 Yr CAGR | Positive |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹100 Cr | 8.13 | |
| Mar2024 | ₹92 Cr | 98.99 | |
| Mar2023 | ₹46 Cr | Positive | |
| Mar2022 | ₹-1.95 Cr | Negative | |
| Mar2021 | ₹-117 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -10.43 % |
| 5 Yr CAGR | Positive |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 10.39 % | -10.43 | |
| Mar2024 | 11.6 % | 39.76 | |
| Mar2023 | 8.3 % | Positive | |
| Mar2022 | -10.17 % | Negative | |
| Mar2021 | -21.16 % | - | |
ORCHID PHARMA Earnings Per Share (EPS)
[BOM: 524372|NSE : ORCHPHARMA]
| Y-o-Y | 8.15 % |
| 5 Yr CAGR | Positive |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹20 | 8.15 | |
| Mar2024 | ₹18 | 60.09 | |
| Mar2023 | ₹11 | Positive | |
| Mar2022 | ₹-0.48 | Negative | |
| Mar2021 | ₹-29 | - | |
ORCHID PHARMA Return on Capital Employed (ROCE)
[BOM: 524372|NSE : ORCHPHARMA]
| Y-o-Y | -13.90 % |
| 5 Yr CAGR | Positive |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 8.05% | -13.90 | |
| Mar2024 | 9.35% | 2.63 | |
| Mar2023 | 9.11% | Positive | |
| Mar2022 | -2.32% | Negative | |
| Mar2021 | -3.53% | - | |
ORCHID PHARMA Share Price vs Sensex
| Current Share Price | : | ₹513.3 |
| Current MarketCap | : | ₹ 2,602.4 Cr |
| Updated EOD on | : | Mar 24,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ORCHID PHARMA | -4.7% |
-23.2% |
-39% |
| SENSEX | -2.6% |
-10.2% |
-1.6% |
ORCHID PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE HEALTHCARE | -1.4% | -2.7% | 3.5% |
| BSE SMALLCAP | -5.8% | -8.9% | -10.5% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MICROCAP 250 | -1.2% | -9.9% | -3.6% |
| NIFTY TOTAL MARKET | -2.7% | -9.6% | 1.8% |
You may also like the below Video Courses
FAQ about ORCHID PHARMA Financials
How the annual revenues of ORCHID PHARMA have changed ?
The Revenues of ORCHID PHARMA have increased by 12.52% YoY .
How the Earnings per Share (EPS) of ORCHID PHARMA have changed?
The Earnings Per Share (EPS) of ORCHID PHARMA has increased by 8.15 % YoY .
Check out Intrinsic Value of Peers of ORCHID PHARMA
Compare Stock Analytics of Peers of ORCHID PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
